ERS International Congress 2023: highlights from the Thoracic Oncology Assembly.

Catarata, Maria Joana; Creamer, Andrew W; Dias, Margarida; Toland, Sile; Chaabouni, Malek; Verbeke, Koen; Vieira Naia, Joana; Hassan, Maged; Naidu, Sindhu Bhaarrati; Lynch, Geraldine A; Blyth, Kevin G; Rahman, Najib M; Hardavella, Georgia.

Afiliação

Catarata MJ; Pulmonology Department, Hospital de Braga, Braga, Portugal.
Creamer AW; Tumour and Microenvironment Interactions Group, I3S - Institute for Health Research and Innovation, University of Porto, Porto, Portugal.
Dias M; Great Western Hospitals NHS Foundation Trust, Swindon, UK.
Toland S; Pulmonology Department, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
Chaabouni M; Department of Medicine, Letterkenny University Hospital, Letterkenny, Ireland.
Verbeke K; Asklepios Klinik Altona, Department of Internal Medicine II, Pulmonology and Thoracic Oncology Section, Hamburg, Germany.
Vieira Naia J; Department of Respiratory Medicine, University Hospital Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium.
Hassan M; Pulmonology Department, Hospital de Braga, Braga, Portugal.
Naidu SB; Chest Diseases Department, Alexandria University Faculty of Medicine, Alexandria, Egypt.
Lynch GA; Department of Respiratory Medicine, University College London, London, UK.
Blyth KG; Academic Respiratory Unit, University of Bristol Medical School, Bristol, UK.
Rahman NM; Queen Elizabeth University Hospital, Glasgow, UK.
Hardavella G; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.

ERJ Open Res ; 10(1)2024 Jan.

Article em En | MEDLINE | ID: mdl-38410708

ABSTRACT

Lung cancer is the leading cause of cancer mortality in the world. It greatly affects the patients' quality of life, and is thus a challenge for the daily practice in respiratory medicine. Advances in the genetic knowledge of thoracic tumours' mutational landscape, and the development of targeted therapies and immune checkpoint inhibitors, have led to a paradigm shift in the treatment of lung cancer and pleural mesothelioma. During the 2023 European Respiratory Society Congress in Milan, Italy, experts from all over the world presented their high-quality research and reviewed best clinical practices. Lung cancer screening, management of early stages of lung cancer, application of artificial intelligence and biomarkers were discussed and they will be summarised here.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article